Johnson & Johnson's Subcutaneous Amivantamab Shows Promising Activity in Hard‑to‑Treat Head and Neck Cancer

The Phase 1b/2 OrigAMI‑4 trial enrolled 102 patients whose disease had progressed after both platinum chemotherapy and PD‑1/PD‑L1 checkpoint blockade. In this population, confirmed overall response rate (ORR) was 42% by blinded independent central review, with complete responses in roughly one‑third of responders (15% of the total cohort). Median follow‑up was 11.8 months and the median duration of response has not yet been reached, suggesting durable activity. Progression‑free survival was 6.8 months and overall survival 12.5 months, outcomes that compare favorably with historical controls where ORR rarely exceeds 24% and five‑year survival hovers around 15%.

Amivantamab is a bispecific antibody that simultaneously blocks EGFR and MET pathways—both implicated in tumor growth and resistance to existing therapies. By delivering the drug subcutaneously with hyaluronidase, the regimen offers a more convenient administration schedule than intravenous infusions, potentially improving patient adherence and reducing infusion‑center burden.

For investors, the data open a new revenue stream beyond the drug’s established role in EGFR‑mutated non‑small cell lung cancer, where it already generates multi‑billion‑dollar sales worldwide. The head‑and‑neck indication addresses an unmet market of roughly 600,000 new cases globally each year, with a sizable subset progressing after standard chemo‑immunotherapy. If the FDA grants approval, Johnson & Johnson could capture a meaningful share of this niche, especially given the lack of any approved EGFR/MET‑targeted therapy in this space.

The company has already submitted a supplemental Biologics License Application (sBLA) that benefits from Breakthrough Therapy Designation, which may accelerate review. Concurrently, Johnson & Johnson is advancing a Phase 3 study (OrigAMI‑5) testing amivantamab with carboplatin and pembrolizumab as first‑line therapy, signaling an intent to position the drug across multiple lines of treatment. Successful outcomes in that trial could further expand market potential and create cross‑indication synergies.

Safety signals remain manageable. Grade 3/4 adverse events were limited; most treatment‑related toxicities (rash, hypoalbuminemia, paronychia) were grade 1–2 and led to discontinuation in only 8% of patients. No new safety concerns emerged versus the lung‑cancer experience, supporting a favorable risk‑benefit profile for clinicians.

From a valuation perspective, analysts project an upside target around $250 per share, implying roughly an 11% premium to the current price of $225. The stock has underperformed the S&P 500 this year and sits near its 52‑week high, suggesting room for upside if regulatory approval materializes. However, investors should weigh execution risk—particularly the FDA’s assessment of efficacy in a relatively small trial—and potential competition from emerging bispecifics targeting similar pathways.

Overall, the pivotal head‑and‑neck data add a compelling growth catalyst to Johnson & Johnson’s oncology pipeline, diversifying its revenue base and offering a differentiated therapy in an area with limited options. The next regulatory milestone will be closely watched by both patients and shareholders.